Therefore, it may be possible to improve the outcome of cases with FLT3-ITD myeloid leukemia using alemtuzumab as a GVHD prophylaxis for patients undergoing allogeneic hematopoietic stem cell transplantation. Here, FLT3 is linked to myeloid leukemia.